How Baum was paid
$23.6M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Mark L. BaumChief Executive Officer | $754,910 | $22,294,873 | — | $542,491 | $14,000 | $23,606,274 |
| Andrew R. BollPresident and Chief Financial Officer | $505,259 | $10,169,924 | — | $258,258 | $14,000 | $10,947,441 |
| Francis W. MulleryPresident and Chief Executive Officer, ImprimisRx Division | $129,808 | — | $1,054,624 | $53,260 | — | $1,237,692 |
| Amir H. ShojaeiChief Scientific Officer | $441,346 | — | $670,569 | $225,000 | $5,712 | $1,342,627 |
| John P. SaharekFormer President and Chief Executive Officer, ImprimisRx Division | $475,614 | — | — | $237,807 | $14,000 | $727,421 |
What changed and why
- $23.6MChief Executive Officer Mark L. Baum received total compensation of $23,606,274 in fiscal 2025, compared to $1,358,490 in fiscal 2024.
- The increase was primarily driven by multi-year performance stock unit awards granted to executives in July 2025.
- Annual cash incentive bonuses were paid at target levels based on performance factors including revenue and adjusted EBITDA.
- The Compensation Committee does not intend to issue equity awards to Messrs.
- Baum or Boll during 2026.
- The ratio of annual total compensation of the CEO to the median employee pay was 263 to 1.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.